Skip to main content

Advertisement

Table 2 Ethnic differences in diarrheal side effects in respondents switching from BID SGCs to BID tablets

From: Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

  BID Respondents (n = 332) White (n = 136) Black (n = 123) Hispanic (n = 67)
Relative Risk (Tablets vs. SGCs)
Antidiarrheal use (more than "rarely use") 0.73* 0.72* 0.95 0.65
Diarrhea frequency 3+ per week 0.60* 0.68* 0.52* 0.39*
Respondent self-defined "severe" diarrhea 0.28* 0.47* 0.13* 0.17*
Proportion of respondents (Tablets vs. SGCs)
Respondent self-defined "severe" diarrhea 3.3% vs. 11.7%* 7% vs. 15%* 1% vs. 8%* 2% vs. 12%*
  1. * p < 0.05